ACG New York Women of Leadership - Entrepreneur Series
Barbara Bradley Baekgaard, founder of Vera Bradley (Nasdaq: VRA), is the latest in a series of entrepreneurs highlighted at ACG New York Women of Leadership events. Photo credit: Robert Blumenfeld


GTCR, Hormel, the Riverside Co-CEOs and Others Win M&A Mid-Market Awards
Amid a slow and challenging year for dealmaking, the winners of Mergers & Acquisitions’ 7th Annual M&A Mid-Market Awards outpaced the competition to grow, innovate and lead the middle market


The Buyside:
Disney, Warner Bros. Seek Next-Gen YouTubes

Traditional Hollywood studios such as Disney and Warner Bros. are seeking next-generation YouTube content providers

The Buyside

Activist Investors Dig Into Mid Market
Spurred on by the high-profile success of Carl Icahn and others, a growing crop of firms is looking further downstream

Today's Transactions:
Amgen Acquires DeCode for $415M

The target focuses on the link between genomes and disease susceptibility

Amgen (Nasdaq: AMGN) will acquire DeCode Genetics for $415 million.

DeCode, headquartered in Reykjavik, Iceland, is a human genetics research company that focuses on the link between genomes and disease susceptibility. The company was founded in 1996 and has discovered risk factors for dozens of diseases.

This year, the company published three studies on Alzheimer’s, the importance of a father’s age linked to disease risk and thyroid cancer risk.

Amgen is a Thousand Oaks, Calif.-based biotechnology company that develops medications for cancer, kidney disease, rheumatoid arthritis, bone disease and other illnesses.

For more coverage on Amgen and the pharmaceutical sector, read Mergers & Acquisitions’Dealmaker of the Year” story highlighting the accomplishments of Roger Perlmutter, Amgen's executive vice president, as well as "The Buyside: Big- and Mid- Market Pharma Grabs Spotlight." 


For more information on related topics, visit the following: